Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qiagen NV

42.75
+0.12000.28%
Pre-market: 44.001.25+2.92%05:51 EDT
Volume:1.01M
Turnover:43.14M
Market Cap:9.24B
PE:112.32
High:43.19
Open:43.16
Low:42.47
Close:42.63
Loading ...

Reported Sunday, QIAGEN Preliminary Q1 2025 Revenue ~$483M And Expects Adj. EPS Of At least $0.55 (Vs. $0.56 Est.); Raised 2025 EPS Target To ~$2.35 (Vs. $2.48 Est.) From Prior $2.28

Benzinga
·
07 Apr

Press Release: QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Dow Jones
·
07 Apr

Qiagen Says Q1 Adjusted EPS $0.55

Reuters
·
07 Apr

Qiagen Cut to Neutral From Buy by Redburn Atlantic

Dow Jones
·
04 Apr

QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Business Wire
·
01 Apr

Bio-Techne Opens New Customer Experience Centre in Germany

Zacks
·
31 Mar

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

Business Wire
·
31 Mar

Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Simply Wall St.
·
29 Mar

HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?

Zacks
·
19 Mar

Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?

Zacks
·
08 Mar

QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel

Zacks
·
07 Mar

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires Live
·
06 Mar

Qiagen announces FDA clearance for QIAstat-Dx Gastrointestinal Panel 2 Mini B

TIPRANKS
·
06 Mar

QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel

MT Newswires Live
·
06 Mar

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

Business Wire
·
06 Mar

Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now

Insider Monkey
·
04 Mar

Qiagen Files Patent Infringement Complaint in Germany Against bioMerieux

MT Newswires Live
·
03 Mar

Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property

Reuters
·
03 Mar

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

Business Wire
·
03 Mar

Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?

Zacks
·
26 Feb